Skip to main content

AstraZeneca and our year in brief

Financial highlights

Growth rates represent underlying performance, which shows growth at constant exchange rates (CER) by excluding the effects of exchange rate movements. Underlying CER growth is calculated by retranslating the current year’s performance at the previous year’s exchange rates and adjusting for other exchange effects, including hedging.

SALES $M

GROWTH
2007 - 29,559 +7%
2006 - 26,475 +11%
2005 - 23,950 +10%

OPERATING PROFIT $M

GROWTH
2007 - 9,060 +8%
2007 - 8,094 -4%
2006 - 8,216 +28%
2005 - 6,502 +39%

PROFIT BEFORE TAX $M

GROWTH
2007 - 8,949 +2%
2007 - 7,983 -9%
2006 - 8,543 +29%
2005 - 6,667 +41%

EARNINGS PER ORDINARY SHARE $

GROWTH
2007 - 4.20 +7%
2007 - 3.74 -5%
2006 - 3.86 +34%
2005 - 2.91 +41%

R&D INVESTMENT $M

GROWTH
2007 - 5,089 +22%
2007 - 5,162 +24%
2006 - 3,902 +16%
2005 - 3,379 -4%

SG&A COSTS $M

GROWTH
2007 - 9,886 +4%
2007 - 10,364 +9%
2006 - 9,096 +5%
2005 - 8,695 +4%

RETURNS TO SHAREHOLDERS – DIVIDENDS AND SHARE RE-PURCHASES $M

2007 - 6,811  
2006 - 6,367  
2005 - 4,718  

1Excluding restructuring and synergy costs.

Back to top ↑